Overview
- Novo’s oral Wegovy, launched earlier this year, is posting stronger early prescription volumes in the oral-pill niche than Lilly’s Foundayo, a dynamic that has shifted short-term market attention toward Novo.
- Eli Lilly remains the broader market leader because its injectable drugs Mounjaro and Zepbound drive larger overall sales and market share gains.
- Company figures cited in coverage show a large difference in patient mix, with Lilly reporting a far higher share of patients who are new to the GLP-1 class than Novo’s oral pill, a factor that affects per-patient revenue and clinical comparisons.
- Analysts warn that growing prescription counts may not translate into durable revenue because U.S. pricing pressure and programs like 340B can reduce margins and lower list-price realization for both companies.
- Investors are debating valuations and outlooks as some make a contrarian case for Novo based on pill momentum and relative valuation while others point to Lilly’s current scale and recent fast growth as the safer long-term position.